WASHINGTON(January 29, 2024) – The Supreme Court has set a date to hear oral arguments on the abortion drug, Mifepristone, in March. Food and Drug Administration v. Alliance for Hippocratic Medicine could lead to ramifications for the FDA, health care providers and patients. This will be the first major test of abortion limits since the same panel overturned Roe v Wade in 2022.
Experts at the George Washington University are available to offer insight, commentary and analysis on the legal and public health aspects of the case. If you wish to speak with an expert, please contact Shannon Mitchell (add in your contact); Kathy Fackelmann, kfackelmann
gwu [dot] edu (kfackelmann[at]gwu[dot]edu) or GW Media Relations at gwmediagwu [dot] edu (gwmedia[at]gwu[dot]edu).
Law
Sonia Suter is The Henry St. George Tucker III Dean’s Research Professor of Law; The Kahan Family Research Professor of Law; Founding Director, Health Law Initiative at the George Washington University Law School. Professor Suter is an expert in the intersection of law, medicine and bioethics with a particular focus on reproductive rights, emerging reproductive technologies, and ethical and legal issues in genetics.Recently, Professor Suter published an op-ed on the topic in The Conversation, “Most state abortion bans have limited exceptions- but it’s hard to understand what they mean.”
Alan Morrison is the Lerner Family Associate Dean for Public Interest and Public Service Law; Professorial Lecturer in Law at the George Washington University Law School. Dean Morrison is expert in constitutional law and has argued in front of the Supreme Court 20 times
Public Health
Julia Strasser is a research professor of health policy and management as well as Director of the Jacobs Institute of Women’s Health at the GW Milken Institute School of Public Health. She is an expert on reproductive health and the abortion provider workforce. She is available to comment on the impact of the Supreme Court Case on women’s health.
Elizabeth Borkowski is a senior research scientist in health policy and management at the GW Milken Institute School of Public Health. Her areas of expertise include reproductive health and U.S. healthcare policy affecting women's health. She is available to comment on the science and safety of mifepristone as well as the FDA approval process.
Borkowski and Strasser are the authors of an op-ed on this topic in Scientific American.
-GW-
